Skip to main content
LNTH
NASDAQ Life Sciences

Lantheus to Divest CDMO Business and New Jersey Plant to PharmaLogic

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$101.05
Mkt Cap
$6.606B
52W Low
$50.155
52W High
$111.86
52W Position info
101% above low
Off High info
9.7% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

LNTH has more than doubled off its 52-week low of $50.155.

Summary

Lantheus agreed to sell its contract development and manufacturing organization business and its Springfield, N.J., manufacturing facility to PharmaLogic under a definitive agreement entered into November 8, 2026, a move that expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies. The sale agreement includes a long-term supply deal under which PharmaLogic's Agilera unit will make lutetium Lu 177 dotatate for Lantheus, with transition services after closing. The deal sheds non-core manufacturing assets while the company is mid-flight on its $8 billion acquisition by Curium, which shareholders approved October 14 and which remains under FTC review after a Second Request. Terms were not disclosed, so the financial impact is unclear, but a divestiture of this type typically simplifies the asset base ahead of the Curium combination. The move follows a Q3 print showing revenue of $389.9 million (+1.5%) and GAAP EPS down 19.5% to $0.33 on impairment and milestone charges.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The PharmaLogic sale agreement includes a long-term supply deal under which PharmaLogic's Agilera unit will make lutetium Lu 177 dotatate for Lantheus, with transition services after closing.

    • Definitive agreement with PharmaLogic Holdings Corp. entered into November 8, 2026.

At the time of this announcement, LNTH was trading at $101.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $50.16 to $111.86. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

LNTH - Latest Insights

LNTH
Nov 05, 2026, 11:24 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $100.97
Real-time Price: $101.63 info
Change: +$0.660 (+0.65%) info
Market Cap: $6.647B info
LNTH
Nov 05, 2026, 7:51 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $100.61
Real-time Price: $101.63 info
Change: +$1.02 (+1%) info
Market Cap: $6.647B info
LNTH
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $100.61
Real-time Price: $101.63 info
Change: +$1.02 (+1%) info
Market Cap: $6.647B info
LNTH
Oct 22, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $100.24
Real-time Price: $101.63 info
Change: +$1.39 (+1%) info
Market Cap: $6.647B info
LNTH
Oct 15, 2026, 7:47 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $100.00
Real-time Price: $101.63 info
Change: +$1.63 (+2%) info
Market Cap: $6.647B info